EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - Generic Drug Details

What are the generic drug sources for emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate and what is the scope of patent protection?

Emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate is the generic ingredient in two branded drugs marketed by Apotex and Gilead Sciences Inc, and is included in two NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

International Patents:	58
US Patents:	2
Tradenames:	2
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE
DailyMed Link:	EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE at DailyMed

Recent Clinical Trials for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gilead Sciences	Phase 3

See all EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE clinical trials

Pharmacology for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Non-Nucleoside Reverse Transcriptase Inhibitors Nucleoside Reverse Transcriptase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J05AG	Non-nucleoside reverse transcriptase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ODEFSEY	Tablets	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	200 mg/25 mg/ 25 mg	208351	3	2019-11-05

US Patents and Regulatory Information for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016		RX	Yes	Yes	8,754,065*PED				Y
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016		RX	Yes	Yes	9,296,769*PED				Y
Apotex	EMTRICITABINE, RILPIVIRINE, AND TENOFOVIR ALAFENAMIDE	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	214095-001	Jan 30, 2026		DISCN	No	No

Expired US Patents for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016	6,838,464
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016	7,803,788
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016	7,125,879
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016	8,080,551
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016	7,067,522
Gilead Sciences Inc	ODEFSEY	emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate	TABLET;ORAL	208351-001	Mar 1, 2016	8,101,629

International Patents for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	3639
Argentina	087546
Australia	2012296622
Australia	2014271320
Brazil	112014003420
Canada	2845553

Supplementary Protection Certificates for EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663240	2015/052	Ireland		PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE, AND EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
1663240	300851	Netherlands		PRODUCT NAME: COMBINATIE VAN: - RILPIVIRINE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, ZOALS EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN RILPIVIRINE, WAARONDER HET HYDROCHLORIDEZOUT VAN RILPIVIRINE; - EMTRICITABINE; EN - TENOFOVIRALAFENAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIRALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/16/1112 20160623
3808743	CA 2022 00035	Denmark		PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A THERAPEUTICALLY EQUIVALENT FORM THEREOF PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIC ACID SALT OF RILPIVIRINE, AND EMTRICITABINE; REG. NO/DATE: EU/1/11/737/001-002 20111128
1663240	1690062-3	Sweden		PRODUCT NAME: A COMBINATION OF: RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE; EMTRICITABINE; AND TENOFOVIR ALAFENAMIDE, OR A PHARMCEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TENOFOVIR ALAFENAMIDE FUMARATE.; REG. NO/DATE: EU/1/16/1112 20160623
0582455	08C0021	France		PRODUCT NAME: EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/07/430/001 20071213
0915894	08C0020	France		PRODUCT NAME: EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/07/430/001 20071213

Emtricitabine, Rilpivirine Hydrochloride and Tenofovir Alafenamide Fumarate: Market Dynamics, Patent Exclusivity and Financial Trajectory

Last updated: September 5, 2026

Odefsey, the fixed-dose combination of emtricitabine, rilpivirine hydrochloride and tenofovir alafenamide fumarate, is a mature Gilead Sciences HIV product with annual sales near or above $1 billion. Its commercial position is supported by once-daily dosing, a lower tenofovir exposure profile than older tenofovir disoproxil fumarate products, and use in virologically suppressed patients. The principal risks are internal cannibalization by Biktarvy, declining demand for older single-tablet regimens, and eventual generic entry after the remaining composition and formulation patents expire.

What drug is protected by the Odefsey patent estate?

Odefsey combines three antiretroviral agents:

Component	Pharmacologic class	Commercial role
Emtricitabine	Nucleoside reverse transcriptase inhibitor	Backbone agent
Tenofovir alafenamide fumarate	Nucleotide reverse transcriptase inhibitor	Lower-systemic-exposure tenofovir prodrug
Rilpivirine hydrochloride	Non-nucleoside reverse transcriptase inhibitor	Non-nucleoside third agent

Gilead launched Odefsey in the United States in March 2016 after FDA approval for HIV-1 treatment in patients weighing at least 35 kilograms who were virologically suppressed on a stable antiretroviral regimen and had no history of treatment failure or resistance to the product’s components [1].

The product’s differentiation is clinical rather than mechanistic. Odefsey is a successor to Complera, which combined emtricitabine, rilpivirine and tenofovir disoproxil fumarate. Replacing tenofovir disoproxil fumarate with tenofovir alafenamide was intended to reduce systemic tenofovir exposure and improve renal and bone safety markers.

When does Odefsey lose exclusivity?

Odefsey’s regulatory exclusivity expired before its principal patent protection. The commercial constraint is therefore patent-based rather than FDA exclusivity-based.

Protection category	Approximate status
FDA approval	March 1, 2016
New chemical entity exclusivity	Not applicable to the already known active ingredients
Three-year clinical-investigation exclusivity	Expired in 2019
Primary product protection	Extends into the early 2030s through tenofovir alafenamide-related patents
Earlier rilpivirine protection	Generally expires earlier, in the late 2020s
Generic competition	More likely after expiration or invalidation of the later combination and tenofovir alafenamide patents

The key commercial date is not the expiration of rilpivirine or emtricitabine patents in isolation. A generic applicant must address the patents listed for the specific Odefsey product, including composition, formulation and method-of-use claims.

Gilead’s patent portfolio for tenofovir alafenamide includes U.S. Patent No. 9,393,208, which has been associated with tenofovir alafenamide composition protection and an expiration date in 2032, subject to statutory adjustments and any applicable patent-term restoration. The Orange Book must be reviewed for the current listed patents, expiration dates and use codes because FDA listings can change over time [2].

What patents protect emtricitabine, rilpivirine and tenofovir alafenamide?

The estate has several layers rather than one controlling patent.

Tenofovir alafenamide patents

Tenofovir alafenamide is the strongest remaining protection layer. Gilead developed the compound as a successor prodrug to tenofovir disoproxil fumarate. Patents covering tenofovir alafenamide, fumarate forms, pharmaceutical compositions and combinations with other antiretrovirals provide the main barrier to early Odefsey substitution.

These patents also support Gilead’s broader HIV portfolio, including Descovy, Genvoya and Biktarvy. The shared technology creates both scale benefits and a legal limitation: invalidation of a core tenofovir alafenamide patent could affect several products simultaneously.

Rilpivirine patents

Rilpivirine originated in the Janssen pharmaceutical business. Earlier patents covering rilpivirine and its hydrochloride form have expiration dates before the latest tenofovir alafenamide patents. Rilpivirine protection therefore has less influence on the ultimate Odefsey loss-of-exclusivity date than the newer tenofovir alafenamide and combination patents.

Rilpivirine’s commercial value is also limited by its clinical restrictions. The drug requires administration with a meal, has a lower resistance barrier than integrase inhibitors, and is unsuitable for patients with high baseline viral loads in certain treatment settings.

Combination and formulation patents

Odefsey may be protected by claims directed to:

• Fixed-dose combinations containing emtricitabine, rilpivirine and tenofovir alafenamide.
• Tablet compositions and excipient systems.
• Specific dosage strengths.
• Methods of treating HIV-1 in virologically suppressed patients.
• Use in patients switching from another stable antiretroviral regimen.
• Manufacturing processes and crystalline or salt forms.

Formulation patents can delay an exact-copy generic even after an active-ingredient patent expires. Their value depends on claim breadth, Orange Book listing status and whether an ANDA applicant can certify that it will market a non-infringing formulation.

What is the Orange Book status of Odefsey?

Odefsey is an FDA-approved small-molecule combination product listed in the Orange Book. It is not a biologic and does not have a Purple Book biosimilar pathway.

An ANDA applicant seeking approval for a generic Odefsey equivalent would generally need to file Paragraph IV certifications against unexpired listed patents or wait until the relevant patents expire. A Paragraph IV notice could trigger patent litigation under the Hatch-Waxman Act and impose a potential 30-month stay of final FDA approval, subject to statutory exceptions and court actions [3].

The practical entry date depends on four events:

1. The ANDA applicant’s filing date.
2. The patents identified in its Paragraph IV certification.
3. Whether Gilead sues within the statutory period.
4. Whether the patents survive invalidity and non-infringement challenges.

No biosimilar litigation is relevant because all three Odefsey ingredients are chemically synthesized small molecules.

Which companies are challenging Odefsey exclusivity?

Generic pharmaceutical companies that routinely challenge Gilead HIV products include Teva, Viatris, Sandoz, Lupin, Cipla and Dr. Reddy’s Laboratories. Publicly disclosed challenges must be distinguished from routine Orange Book certifications because a certification does not establish that an ANDA has received FDA approval or that commercial launch is imminent.

The competitive pathway is likely to develop in stages:

Period	Expected market event
Before 2027	Limited direct generic threat if later Odefsey patents remain enforceable
Late 2020s	Greater potential for rilpivirine-related and older combination challenges
Early 2030s	Highest probability of full Odefsey generic entry if tenofovir alafenamide patents remain intact
Post-entry	Rapid price erosion, formulary substitution and reduced branded share

An authorized generic is also possible. Gilead could license a generic manufacturer or launch a company-authorized version to retain supply-chain control and capture part of the post-exclusivity market.

What is the financial trajectory for Odefsey?

Odefsey has moved from growth product to mature franchise asset. Its revenue trajectory reflects both strong retention among stable patients and substitution by newer integrase inhibitor-based regimens.

Approximate Gilead-reported U.S. and international product sales have followed this pattern:

Fiscal year	Odefsey sales trend
2020	Approximately $1.1 billion
2021	Approximately $1.3 billion
2022	Approximately $1.3 billion
2023	Approximately $1.2 billion
2024	Approximately $1.1 billion

Gilead’s annual reports identify Odefsey as part of the company’s HIV product portfolio and report product-level sales alongside Biktarvy, Descovy, Genvoya and Triumeq [4-8]. Reported totals can vary by geographic presentation, foreign-exchange effects and product classification.

The revenue profile has three defining characteristics:

High cash generation

Odefsey has already absorbed most development and launch costs. Manufacturing is established, the product is distributed globally, and the fixed-dose tablet requires no complex biologic production. Gross margins are therefore materially higher than during the launch period.

Gradual erosion rather than immediate collapse

Odefsey is prescribed to patients who are stable and virologically suppressed. Physicians may avoid switching such patients absent a clinical or economic reason. That creates persistence and slows the decline caused by Biktarvy substitution.

Portfolio cannibalization

Biktarvy is Gilead’s main growth product in HIV. Its bictegravir-based regimen has a high resistance barrier and strong treatment positioning. Gilead benefits from retaining patients within its portfolio, but Biktarvy growth reduces the long-term addressable population for Odefsey.

How does Odefsey compare with Biktarvy and Descovy?

Product	Active ingredients	Main positioning	Relative commercial risk
Odefsey	Emtricitabine, rilpivirine, TAF	Single-tablet regimen for selected suppressed patients	Mature product; exposed to Biktarvy switching and future generics
Biktarvy	Bictegravir, emtricitabine, TAF	Broadly used integrase inhibitor regimen	Gilead’s strongest HIV growth and revenue product
Descovy	Emtricitabine, TAF	HIV treatment backbone and pre-exposure prophylaxis	Larger addressable market and multiple indications
Genvoya	Elvitegravir, cobicistat, emtricitabine, TAF	Earlier TAF-based single-tablet regimen	More exposed to aging and switching
Complera	Emtricitabine, rilpivirine, TDF	Predecessor to Odefsey	Mostly legacy demand

Biktarvy has the strongest competitive position because integrase inhibitor regimens have become the preferred initial treatment class in major guidelines. Odefsey remains relevant for patients who are already suppressed, prefer a non-integrase regimen, or have specific treatment-history considerations.

Descovy has broader strategic importance because TAF is used across HIV treatment and prevention markets. This gives Gilead a larger platform around TAF than Odefsey alone.

What licensing deals affect Odefsey?

Odefsey reflects a Gilead-Janssen commercial relationship. Janssen contributed rilpivirine, while Gilead supplied emtricitabine and tenofovir alafenamide and commercialized the fixed-dose product. Earlier products containing rilpivirine, including Complera and Eviplera, were developed through Gilead and Janssen collaboration arrangements.

The economics of such arrangements can include royalties, profit sharing or regional commercialization rights. The exact financial terms are generally not disclosed at the individual-product level in Gilead’s public filings. Investors should therefore treat Odefsey revenue as a Gilead product-sales metric rather than as a direct measure of Gilead’s net retained profit.

What litigation and settlement risks affect generic launch?

The principal legal risks are standard Hatch-Waxman risks:

• Paragraph IV invalidity challenges against TAF composition patents.
• Non-infringement claims directed to fixed-dose tablet patents.
• Challenges to method-of-use patents through skinny-label strategies.
• Disputes over whether a patent is properly listed in the Orange Book.
• Settlements that permit an earlier launch before the nominal patent expiration date.

A settlement could produce a launch date materially earlier than 2032 while preserving Gilead’s patent rights against other generic applicants. The commercial outcome would depend on whether the first filer receives 180-day generic exclusivity and whether multiple challengers enter simultaneously.

What generic entry risks exist for Odefsey?

The likely launch scenarios are:

Scenario	Commercial effect
No challenge until late patent life	Odefsey retains substantial branded revenue through the early 2030s
Single first-filer settlement	Controlled erosion after an agreed entry date
Multiple successful Paragraph IV challenges	Earlier and sharper price decline
TAF patent invalidation	Accelerated risk across Odefsey, Descovy and Genvoya
Authorized generic launch	Lower net price but partial retention of Gilead economics

Once multiple generics enter, branded HIV products can experience significant volume loss. However, payer substitution may be slower than in acute-care markets because clinicians and patients place high value on continuity of virologic suppression.

How strong is the Odefsey patent estate?

The estate is moderate to strong through the early 2030s, principally because the commercial product incorporates the newer TAF prodrug. Its strength is reduced by three factors:

1. The active ingredients are individually well known.
2. Earlier rilpivirine and emtricitabine protection expires sooner.
3. Generic applicants can design around certain formulation and method-of-use claims.

The strongest legal assets are likely the composition and combination patents tied to TAF. The weakest assets are narrow formulation claims and method-of-use claims that can be avoided through alternative labeling or tablet design.

Key Takeaways

• Odefsey is a mature, billion-dollar HIV product marketed by Gilead Sciences.
• Its principal commercial value comes from durable patient retention and established use in virologically suppressed patients.
• Biktarvy is the main internal competitor and the primary source of long-term cannibalization.
• The product has no biosimilar risk because it is a small-molecule combination.
• Earlier emtricitabine and rilpivirine protections are less important than TAF composition and combination patents.
• The most important remaining patent protection extends into the early 2030s, subject to Orange Book changes, patent-term adjustments and litigation.
• A Paragraph IV challenge could move generic entry forward, but the timing would depend on litigation and settlement outcomes.
• TAF patent invalidation would have consequences beyond Odefsey because Descovy and Genvoya also depend on the same technology platform.
• Revenue is likely to decline gradually before generic entry and more sharply after multiple generic suppliers enter.

FAQs

Is Odefsey still a major Gilead product?

Yes. Odefsey remains a significant HIV product with annual sales around $1 billion, although Biktarvy has become Gilead’s principal HIV growth driver.

Is there a generic version of Odefsey?

A fully substitutable generic Odefsey product has not become a major commercial competitor. Generic entry depends on ANDA approvals, Orange Book patent certifications and resolution of any Hatch-Waxman litigation.

Does Odefsey have biosimilar competition?

No. Odefsey contains chemically synthesized small molecules. Competition proceeds through the ANDA generic-drug pathway, not the biosimilar pathway.

Can a generic omit rilpivirine and still compete with Odefsey?

A product that omits rilpivirine would not be an Odefsey-equivalent generic. It could compete therapeutically as a different antiretroviral regimen but would not receive an AB rating to Odefsey.

What is the biggest financial risk to Odefsey?

The largest risk is cumulative portfolio substitution by Biktarvy before full patent expiry, followed by rapid price erosion if a generic applicant successfully challenges the remaining TAF-related patents.

References

1. U.S. Food and Drug Administration. (2016). Odefsey prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application and patent certification provisions. https://www.fda.gov/drugs
4. Gilead Sciences, Inc. (2021). 2020 annual report. https://investors.gilead.com
5. Gilead Sciences, Inc. (2022). 2021 annual report. https://investors.gilead.com
6. Gilead Sciences, Inc. (2023). 2022 annual report. https://investors.gilead.com
7. Gilead Sciences, Inc. (2024). 2023 annual report. https://investors.gilead.com
8. Gilead Sciences, Inc. (2025). 2024 annual report. https://investors.gilead.com